Antiretroviral treatment for HIV infection: Swedish recommendations 2019.
Antiretroviral
HIV
Sweden
adult
paediatric
treatment guidelines
Journal
Infectious diseases (London, England)
ISSN: 2374-4243
Titre abrégé: Infect Dis (Lond)
Pays: England
ID NLM: 101650235
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
pubmed:
14
1
2020
medline:
13
4
2021
entrez:
14
1
2020
Statut:
ppublish
Résumé
The Swedish Reference Group for Antiviral Therapy (RAV) published recommendations for the treatment of HIV infection in this journal most recently in 2017. An expert group under the guidance of RAV here provides updated recommendations. The most important updates in the present guidelines are the following: (a) The risk of HIV transmission through condomless sex from individuals with fully suppressed HIV viral load is effectively zero. (b) Pre-exposure prophylaxis (PrEP) is recommended for groups with a high risk of HIV infection. (c) Since the last update, two new substances have been registered: bictegravir and doravirine. (d) Dual treatment may be an alternative in selected patients, using lamivudine + dolutegravir or lamivudine + boosted darunavir/atazanavir. As with previous publications, recommendations are evidence-graded in accordance with the Oxford Centre for Evidence Based Medicine. This document does not cover treatment of opportunistic infections and tumours.
Identifiants
pubmed: 31928282
doi: 10.1080/23744235.2019.1707867
doi:
Substances chimiques
Anti-HIV Agents
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM